Brief: Alligator Bioscience Receives EMA Orphan Designation For Mitazalimab
21/08/2023 07:47
Aug 21 (Reuters) - Alligator Bioscience AB ATORX.ST :
* ALLIGATOR BIOSCIENCE RECEIVES EUROPEAN MEDICINE AGENCY
ORPHAN
DESIGNATION FOR MITAZALIMAB IN PANCREATIC CANCER
* OPTIMIZE-1 IS ON TRACK FOR TOP-LINE READOUT IN EARLY Q1
2024
Source text for Eikon: ID:nMFN7lLzYp
Further company coverage: ATORX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Alligator Bioscience AB
See all newsBrief: Alligator Bioscience Q1 Net Loss SEK 1.4 Million
Sweden's Alligator Bioscience posts Q1 net profit, narrows operating loss
Brief: Alligator Bioscience Q1 EBIT SEK -17.8 Million
Brief: Alligator Bioscience Signs LoI With Unicancer For Phase 3 Mitazalimab Development
Brief: Exercise Of Warrants Brings Alligator Bioscience Net Proceeds Of SEK 12 Mln